Volume 10, Number 3—March 2004
Perspective
Clinical Trials and Novel Pathogens: Lessons Learned from SARS
Matthew P. Muller*‡, Allison McGeer*‡, Sharon E. Straus†‡, Laura Hawryluck†‡, and Wayne L. Gold†‡
Table
Eligible cases lost to enrollment in a hypothetical trial of ribavirin during the first outbreak of SARS in Toronto.
| Date from outbreak recognition to date of enrollment of first patient (days) | Number of cases lost to enrollment (%) |
|---|---|
| March 13–16 (3) |
6/249 (2) |
| March 13–20 (7) |
37/249 (15) |
| March 13–23 (10) |
62/249 (25) |
| March 13–28 (15)a |
114/249 (46) |
| March 13–31 (18)b | 149/249 (60) |
aApproval from first local ethics review board
bApproval from Health Canada
Page created: February 08, 2011
Page updated: February 08, 2011
Page reviewed: February 08, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.